Physician profile
Weiming David Chu
NPI 1114189529
$2,921.31
in general payments reported to CMS, 2019-2025
10 companies · $530 in 2025
The $530 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $616 · 2020: $119 · 2021: $70.06 · 2022: $98.82 · 2023: $782 · 2024: $705 · 2025: $530.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,017.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,017.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,295.50 | 2019-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Alkermes, INC. | $147.03 | 2019 | |
| Avanir Pharmaceuticals, INC. | $125.59 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $113.50 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $67.69 | 2019 | |
| Acadia Pharmaceuticals INC | $59.12 | 2019-2023 | Nuplazid |
| Neuronetics, INC. | $58.45 | 2023 | Neurostar Tms Therapy System |
| Sun Pharmaceutical Industries INC. | $20.54 | 2021 | |
| Neurocrine Biosciences, INC. | $20.12 | 2024 | Ingrezza |
| Vanda Pharmaceuticals INC. | $13.77 | 2024 | Fanapt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Weiming David Chu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.